Dr. Carlos Chaccour, PhD
Dr. Carlos Chaccour, PhD, Assistant Research Professor, Barcelona Institute for Global Health, and Chief Scientific Officer of the Unitaid-funded BOHEMIA consortium project in Barcelona, Spain, is a scientist and researcher whose primary area of scientific interest is with Emerging Viruses, Malaria, and Coronavirus.
For the last 10 years, his most intense professional focus has been upon “the development of mosquito-killing drugs (endectocides) as complementary vector control strategy for malaria control and elimination.” In fact, the specific area in which he “obtained his PhD in 2015, was working with slow-release ivermectin formulations for that purpose.”
Dr. Joe Brew, PhD
In May 2020, he, along with fellow researchers Dr. Joe Brew, PhD, a Data Scientist, Epidemiologist, and Economist; and Dr. Alberto García-Basteiro, MD, Assistant Research Professor at the Barcelona Institute for Global Health, ISGlobal in Barcelona, Spain, and physician at the International Health Service of Hospital Clínic, authored “Ivermectin and COVID-19: How a Flawed Database Shaped the Pandemic Response of Several Latin-American Countries.”
Dr. Alberto Garcia-Basteiro, MD
Their critical examination was in response to efforts by healthcare professionals and officials in the nations of Peru, Bolivia, Paraguay, and Colombia who suddenly began taking an unusual interest in ivermectin, and using it on COVID-19 patients in their respective nations. Those nations’ officials were motivated, in large part by a since-retracted, and debunked manuscript initially placed on a “preprint server,” a website which publishes online, a full draft of research which has not yet been validated by the peer-review process. The respected healthcare/medical science journal Lancet, which has been continually published since 1823 with the objective to improve people’s lives, states that “a preprint is a version of a scientific manuscript posted on a public server prior to any formal peer review.”
Specifically, Dr. Chaccour and colleagues examined antiviral research published June 2020 in Science Direct entitled “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,” i.e., in glass, such as test tube, beaker, or Petri dish, which was performed early in April by Australian researchers Leon Caly, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, Australia, Julian D. Druce, Senior Medical Scientist in the Virus Identification Laboratory of the Victorian Infectious Diseases Reference Laboratory, et al, which “used concentrations that are not readily achieved in the human body” but raised enough interesting questions that further investigation was warranted, and because of “the drug’s excellent safety profile and lack of effective treatment for COVID-19.”
In response to their critical examination, and genuine questions about the techniques and methods, they wrote a guest editorial entitled “Ivermectin and COVID-19: Keeping Rigor in Times of Urgency” which was Read the rest of this entry »
Warm Southern Breeze 